Back to top
more

Bruker (BRKR)

(Delayed Data from NSDQ)

$64.54 USD

64.54
1,334,767

+0.81 (1.27%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $64.54 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 250)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Grows on Innovation & International Growth

by Zacks Equity Research

Illumina (ILMN) is benefiting from sturdy demand for sequencing and array systems as well as consumables and services.

NuVasive (NUVA) Launches Pulse Integrated Technology Platform

by Zacks Equity Research

The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.

Boston Scientific's Global Growth Robust Amid Currency Woe

by Zacks Equity Research

Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.

Has Bruker (BRKR) Outpaced Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (BRKR) Outperforming Other Computer and Technology Stocks This Year?

Medtronic Releases Positive Results of LATERAL Clinical Trial

by Zacks Equity Research

Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.

ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite

by Zacks Equity Research

ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.

Integra Partners AI-Driven Data Analytics Firm in Wound Care

by Zacks Equity Research

Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.

Phibro Animal Sees Crucial Progress in ASF Vaccine Development

by Zacks Equity Research

The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.

Fresenius Set for Global Expansion of Research Activities

by Zacks Equity Research

Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.

Illumina (ILMN) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Illumina (ILMN) gains from expansion of its product portfolio and strategic partnership.

CVS Health Banks on Aetna Prospects, Omnicare May Disappoint

by Zacks Equity Research

CVS Health's (CVS) Aetna integration synergies bode well for the stock.

Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

by Zacks Equity Research

The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

Here's Why CVS Health (CVS) Should Be in Your Portfolio

by Zacks Equity Research

Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.

Here's Why Chemed (CHE) Should Remain in Your Portfolio Now

by Zacks Equity Research

Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.

David Bartosiak headshot

Five Runaway Breakout Stocks to Buy

by David Bartosiak

With the market at all-time highs again, the rich get richer as stocks continue to breakout.

Here's Why Bruker (BRKR) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: Universal Display, Bruker, Match, j2 and Ciena

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Universal Display, Bruker, Match, j2 and Ciena

Swarup Gupta headshot

5 Top Tech Gainers of 1H19

by Swarup Gupta

The Technology Select Sector SPDR Fund (XLK) is the leading performer among the S&P 500's 11 sectors year to date.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Teleflex (TFX) Shares Down on Respiratory Care Product Recall

by Zacks Equity Research

Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.

Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Bruker (BRKR) gains from several crucial product launches and acquisitions.

All You Need to Know About Bruker (BRKR) Rating Upgrade to Strong Buy

by Zacks Equity Research

Bruker (BRKR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Methode Electronics (MEI) Q4 Earnings Lag, Sales Up Y/Y

by Zacks Equity Research

Methode Electronics' (MEI) fourth-quarter fiscal 2019 results suffer from weak automotive sales stemming from lower demand for passenger cars.

Bruker (BRKR) Launches the MALDI Biotyper Sirius System

by Zacks Equity Research

The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.

IDEXX (IDXX) Gains Traction From Solid CAG, Global Strength

by Zacks Equity Research

IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.